Cited by 253Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record, with a small difference in title or year; 42 of the 43 references it cites were found in a registry or an index.

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial

Open access

Tanum, Lars, Solli, Kristin Klemmetsby, Latif, Zill-e-Huma, Benth, Jurate Šaltyte, Opheim, Arild, Sharma-Haase, Kamni, Krajci, Peter, Kunøe, Nikolaj·2017·JAMA Psychiatry

DOI 10.1001/jamapsychiatry.2017.3206PMC PMC6583381

Open this paper in CoChat — free account Open PDF

Abstract

Importance: To date, extended-release naltrexone hydrochloride has not previously been compared directly with opioid medication treatment (OMT), currently the most commonly prescribed treatment for opioid dependence. Objective: To determine whether treatment with extended-release naltrexone will be as effective as daily buprenorphine hydrochloride with naloxone hydrochloride in maintaining abstinence from heroin and other illicit substances in newly detoxified individuals. Design, Setting and Participants: A 12-week, multicenter, outpatient, open-label randomized clinical trial was conducted at 5 urban addiction clinics in Norway between November 1, 2012, and December 23, 2015; the last follow-up was performed on October 23, 2015. A total of 232 adult opioid-dependent (per DSM-IV criteria) individuals were recruited from outpatient addiction clinics and detoxification units and assessed for eligibility. Intention-to-treat analyses of efficacy end points were performed with all randomized participants. Interventions: Randomization to either daily oral flexible dose buprenorphine-naloxone, 4 to 24 mg/d, or extended-release naltrexone hydrochloride, 380 mg, administered intramuscularly every fourth week for 12 weeks. Main Outcomes and Measures: Primary end points (protocol) were the randomized clinical trial completion rate, the proportion of opioid-negative urine drug tests, and number of days of use of heroin and other illicit opioids. Secondary end points included number of days of use of other illicit substances. Safety was assessed by adverse event reporting. Results: Of 159 participants, mean (SD) age was 36 (8.6) years and 44 (27.7%) were women. Eighty individuals were randomized to extended-release naltrexone and 79 to buprenorphine-naloxone; 105 (66.0%) completed the trial. Retention in the extended-release naltrexone group was noninferior to the buprenorphine-naloxone group (difference, -0.1; with 95% CI, -0.2 to 0.1; P = .04), with mean (SD) time of 69.3 (25.9) and 63.7 (29.9) days, correspondingly (P = .33, log-rank test). Treatment with extended-release naltrexone showed noninferiority to buprenorphine-naloxone on group proportion of total number of opioid-negative urine drug tests (mean [SD], 0.9 [0.3] and 0.8 [0.4], respectively, difference, 0.1 with 95% CI, -0.04 to 0.2; P < .001) and use of heroin (mean difference, -3.2 with 95% CI, -4.9 to -1.5; P < .001) and other illicit opioids (mean difference, -2.7 with 95% CI, -4.6 to -0.9; P < .001). Superiority analysis showed significantly lower use of heroin and other illicit opioids in the extended-release naltrexone group. No significant differences were found between the treatment groups regarding most other illicit substance use. Conclusions and Relevance: Extended-release naltrexone was as effective as buprenorphine-naloxone in maintaining short-term abstinence from heroin and other illicit substances and should be considered as a treatment option for opioid-dependent individuals. Trial Registration: clinicaltrials.gov Identifier: NCT01717963.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2017.3206

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Untitled work
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Untitled work
(1998) · PubMed · Cited by 10,216
The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974) · Behavioral Science · doi:10.1002/bs.3830190102 · Cited by 4,604
Timeline Follow-Back
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C. L., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,312
New Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503
A Medical Treatment for Diacetylmorphine (Heroin) Addiction: A Clinical Trial With Methadone Hydrochloride
Dole, V. P. (1965) · JAMA · doi:10.1001/jama.1965.03090080008002 · Cited by 1,240
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,014
Timeline Follow-Back: A Technique for Assessing Self-Reported Alcohol Consumption
Sobell, L. C., & Sobell, M. B. (1992) · NSUWorks (Nova Southeastern University) · Cited by 779

Flagged first, then by citations

Show all 43 references

1 of the 43 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 253

‘Not at all what I had expected’: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study
Brenna, I. H., Marciuch, A., Birkeland, B., Veseth, M., Røstad, B. K., Løberg, E., Solli, K. K., Tanum, L., & Weimand, B. M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108667 · Cited by 18
Self-citation
Rapid Initiation of Injection Naltrexone for Opioid Use Disorder
Shulman, M., Greiner, M. G., Tafessu, H. M., Opara, O., Ohrtman, K., Potter, K. M., Hefner, K. R., Jelstrom, E., Rosenthal, R. N., Wenzel, K. R., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.9744 · Cited by 17
Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study)
Weimand, B. M., Solli, K. K., Reichelt, W. H., & Tanum, L. (2021) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2021.100728 · Cited by 16
Self-citation
Nowhere to go? Examining facility acceptance levels for serving individuals using medications for opioid used disorder
Kepple, N. J., Parker, A., Whitmore, S., & Comtois, M. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.06.004 · Cited by 17
Drug Policy and the Public Good: a summary of the second edition
Babor, T. F., Caulkins, J. P., Fischer, B., Foxcroft, D., Medina‐Mora, M. E., Obot, I. S., Rehm, J. T., Reuter, P., Room, R., Rossow, I. M., et al. (2019) · Addiction · doi:10.1111/add.14734 · Cited by 17
Neuropsychological impairment associated with substance use by physicians
Polles, A., Williams, M. K., Phalin, B. R., Teitelbaum, S. A., & Merlo, L. J. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116714 · Cited by 19
Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone
Ruglass, L. M., Scodes, J. M., Pavlicová, M., Campbell, A. N. C., Fitzpatrick, S., Barbosa‐Leiker, C., Burlew, A. K., Greenfield, S. F., Rotrosen, J., & Nunes, E. V. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107649 · Cited by 16
Chronic Pain, Opioid Use Disorder, and Clinical Management Among Older Adults
Potru, S., & Tang, Y. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210002 · Cited by 18
Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder
Qian, G. L., Rao, I. J., Humphreys, K. N., Owens, D. K., & Brandeau, M. L. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109762 · Cited by 15
A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder
Sibai, M., Mishlen, K., Nunes, E. V., LEVIN, F. R., Mariani, J. J., & Bisaga, A. M. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1700265 · Cited by 15
Demographic and socioeconomic correlates to buprenorphine access in pharmacies
Welsh, J. W., Yarbrough, C. R., Sitar, S. I., Mataczynski, M. J., Peralta, A. M., Kan, M., Crawford, N. D., Conrad, T. A., Kee, C., & Young, H. N. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.12.015 · Cited by 14
Untitled work
(2018) · PubMed · Cited by 14
Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Ross, R. K., Nunes, E. V., Olfson, M., Shulman, M., Krawczyk, N., Stuart, E. A., & Rudolph, K. E. (2024) · Addiction · doi:10.1111/add.16630 · Cited by 13
Treating Opioid Use Disorder in General Medical Settings
(2021) · Springer eBooks · doi:10.1007/978-3-030-80818-1 · Cited by 13
Characteristics and experiences of buprenorphine-naloxone use among polysubstance users
Walker, R., Logan, T., Chipley, Q. T., & Miller, J. (2018) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2018.1461876 · Cited by 13
Provider-directed marketing may increase prescribing of medications for opioid use disorder
Nguyen, T. D., Andraka‐Christou, B., Simon, K. I., & Bradford, W. D. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.06.014 · Cited by 13
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
Comer, S. D., Mannelli, P., Alam, D., Douaihy, A. B., Nangia, N., Akerman, S. C., Zavod, A., Silverman, B. L., & Sullivan, M. A. (2020) · American Journal on Addictions · doi:10.1111/ajad.13024 · Cited by 13
Assessing the impact of drug courts on provider-directed marketing efforts by manufactures of medications for the treatment of opioid use disorder
Andraka‐Christou, B., Nguyen, T. D., Bradford, D. W., & Simon, K. I. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.12.004 · Cited by 12
Pain is reduced by transcutaneous cervical vagus nerve stimulation and correlated with cardiorespiratory variability measures in the context of opioid withdrawal
Gazi, A. H., Harrison, A. B., Lambert, T. P., Nawar, A., Obideen, M., Driggers, E. G., Vaccarino, V., Shah, A. J., Rozell, C. J., Bikson, M., et al. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.1031368 · Cited by 12
Patients’ experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study
Marciuch, A., Brenna, I. H., Weimand, B. M., Solli, K. K., Tanum, L., Røstad, B. K., & Birkeland, B. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00317-2 · Cited by 12
Self-citation
Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone
Solli, K. K., Opheim, A., Latif, Z.-E.-H., Krajči, P., Benth, J. Š., Kunøe, N., & Tanum, L. (2020) · Addiction · doi:10.1111/add.15378 · Cited by 12
Self-citation
Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions
Ghosh, A., Basu, D., & Avasthi, A. (2018) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_218_17 · Cited by 12
Characteristics and circumstances of death related to buprenorphine toxicity in Australia
Darke, S. G., Duflou, J. A., Larance, B., Farrell, M., & Lappin, J. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108360 · Cited by 11
Adherence to extended release naltrexone: Patient and treatment characteristics
Chang, G., Crawford, M. B., Pitts, M., Schein, A. Z., Goodwin, K., & Enggasser, J. L. (2018) · American Journal on Addictions · doi:10.1111/ajad.12786 · Cited by 11
Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone
Karlsson, A. T., Vederhus, J., Clausen, T., Weimand, B. M., Solli, K. K., & Tanum, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194558 · Cited by 11
Self-citation
Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
Dahlberg, S., Chang, E. T., Weiss, S. R., Dopart, P. J., Gould, E. M., & Ritchey, M. E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s381652 · Cited by 10
Medication for the Treatment of Opioid Use Disorder
Renner, J. A., & Crawford, M. B. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-16257-3_5 · Cited by 11
Optimally Choosing Medication Type for Patients With Opioid Use Disorder
Rudolph, K. E., Williams, N., Diaz, I. M., Luo, S. X., Rotrosen, J., & Nunes, E. V. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac217 · Cited by 10
Prevalence and Treatment of Substance Misuse in Older Adults: Beyond Early Adulthood
Hu, J., Kulkarni, N., Maliha, P., & Grossberg, G. T. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s375653 · Cited by 9
Medial prefrontal neuroplasticity during extended-release naltrexone treatment of opioid use disorder – a longitudinal structural magnetic resonance imaging study
Shi, Z., Li, X., Todaro, D. R., Cao, W., Lynch, K. G., Detre, J. A., Loughead, J., Langleben, D. D., & Wiers, C. E. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03061-0 · Cited by 9
Extended-release naltrexone: good but not a panacea
Lott, D. C. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32872-6 · Cited by 9
Risk of Relapse Among Opioid‐Dependent Patients Treated With Extended‐Release Naltrexone or Buprenorphine‐Naloxone: A Randomized Clinical Trial
Opheim, A., Gaulen, Z., Solli, K. K., Latif, Z.-E.-H., Fadnes, L. T., Benth, J. Š., Kunøe, N., & Tanum, L. (2021) · American Journal on Addictions · doi:10.1111/ajad.13151 · Cited by 9
Self-citation
Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis
Hoffman, K. A., Baker, R., Fanucchi, L. C., Lum, P. J., Kunkel, L. E., Terashima, J. P., McCarty, D. W., Jacobs, P., & Korthuis, P. T. (2021) · Addiction Science & Clinical Practice · doi:10.1186/s13722-021-00277-z · Cited by 9
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder
Lier, A., Seval, N., Wyk, B. V., Paola, A. D., & Springer, S. A. (2022) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2022.108852 · Cited by 9
Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review
Chan, B. L., Gean, E. G., Arkhipova-Jenkins, I., Gilbert, J., Hilgart, J., Fiordalisi, C. V., Hubbard, K., Brandt, I., Stoeger, E., Paynter, R. A., et al. (2020) · doi:10.23970/ahrqepcrapidmat · Cited by 9
Extended‐release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review
Woods, A., Foley, C., Conigrave, K. M., Asare‐Doku, W., Shakeshaft, A. P., Settumba, S. N., Farrell, M., & Doyle, M. (2025) · Addiction · doi:10.1111/add.16766 · Cited by 11
Sustained-release naltrexone for opioid dependence
Kornør, H., Lobmaier, P. P. K., & Kunøe, N. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006140.pub3 · Cited by 9
Self-citation
Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials
Shulman, M., Hu, M., Sullivan, M. A., Akerman, S. C., Fratantonio, J. L., Barbieri, V. A., Nunes, E. V., & Bisaga, A. M. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109343 · Cited by 8
Factors influencing recruitment to a randomised placebo-controlled trial of oral naltrexone and extended release implant naltrexone: Qualitative study
Tompkins, C. N. E., Neale, J., Marsden, J., & Strang, J. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.01.012 · Cited by 8
Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
Jain, P., McKinnell, K., Marino, R., Vunnava, P., Liles-Burden, M. A., Desai, A., Wenten, M., Fratantonio, J. L., Akerman, S. C., Sullivan, M. A., et al. (2020) · Drug Safety · doi:10.1007/s40264-020-01020-4 · Cited by 8
Behavioral and Accumbal Responses During an Affective Go/No-Go Task Predict Adherence to Injectable Naltrexone Treatment in Opioid Use Disorder
Shi, Z., Jagannathan, K., Wang, A.-L., Fairchild, V. P., Lynch, K. G., Suh, J. J., Childress, A. R., & Langleben, D. D. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz002 · Cited by 8
Misclassification of overdose events in the X:BOT study
Dasgupta, N., Ajazi, E., Schwartz, T. A., & Marshall, S. W. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00113-7 · Cited by 8
Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross‐sectional study of a state all‐payer claims database
Simon, L. E., Choudhary, A., Ticku, S., Barrow, J. R., & Tobey, M. L. (2021) · Journal of Public Health Dentistry · doi:10.1111/jphd.12488 · Cited by 7
Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
Li, X., Langleben, D. D., Lynch, K. G., Wang, G., Elman, I., Wiers, C. E., & Shi, Z. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1247961 · Cited by 7
Noninvasive Vagal Nerve Stimulation for Opioid Use Disorder
Bremner, J. D. (2023) · Annals of Depression and Anxiety · doi:10.26420/anndepressanxiety.2023.1117 · Cited by 7
Empirically contrasting urine drug screening‐based opioid use disorder treatment outcome definitions
Brandt, L., Odom, G., Hu, M., Castro, C., Balise, R. R., & the CTN‐0094 Team (2024) · Addiction · doi:10.1111/add.16494 · Cited by 7
A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone
Wenzel, K. R., Thomas, J. L., Carrano, J., Stidham, J., & Fishman, M. J. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209366 · Cited by 7
Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study
Brenna, I. H., Waleur, K. M., Benth, J. Š., Solli, K. K., Mordal, J., Løberg, E., Weimand, B. M., & Tanum, L. (2024) · European Addiction Research · doi:10.1159/000541431 · Cited by 7
Self-citation
Patient experience of opioid use disorder treatment medications: a systematic review of contemporary qualitative research
Lowry, N., Najia, C., Kelleher, M., Mitcheson, L., & Marsden, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088617 · Cited by 8
What lessons from Norway’s experience could be applied in the United States in response to the addiction and overdose crisis?
Clausen, T. (2022) · Addiction · doi:10.1111/add.15845 · Cited by 7
Gender differences among persons entering medication treatment for opioid use disorder in the community
Paola, A. D., Taweh, N., Biondi, B. E., Forray, A., Frank, C. A., Shaw, A. C., & Springer, S. A. (2022) · American Journal on Addictions · doi:10.1111/ajad.13304 · Cited by 7
Four models of pharmacist‐integrated office‐based opioid treatment
Caron, O., Fay, A. E., Pressley, H., Seamon, G., Taylor, S. R., & Wilson, C. G. (2022) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1607 · Cited by 7
Commentary on Ajazi et al (2021) Re-analysis of the X:BOT Trial
Lee, J. D., Nunes, E. V., Novo, P., May, J. M., Matthews, A. G., Veldhuisen, P. C. V., Lindblad, R., Liu, D., & Rotrosen, J. (2021) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000930 · Cited by 7
Effectiveness of Mutual Help Groups for Illicit Drug Use Disorders: A Review of the Current Literature
Kepner, W. E., & Humphreys, K. N. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00635-w · Cited by 6
High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study
Mordal, J., Juya, F., Holtan, L., Vederhus, J., Opheim, A., Brenna, I. H., Enger, A., Weimand, B. M., Solli, K. K., & Tanum, L. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00576-9 · Cited by 6
Self-citation
Opioid use disorder: a neglected human immunodeficiency virus risk in American adolescents
Lloyd, A. R., Savage, R. J., & Eaton, E. (2021) · AIDS · doi:10.1097/qad.0000000000003051 · Cited by 6
A Patient-Centered Nurse-Supported Primary Care-Based Collaborative Care Program to Treat Opioid Use Disorder and Depression; Design and Protocol for the MI-CARE Randomized Controlled Trial
DeBar, L., Bushey, M. A., Kroenke, K., Bobb, J. F., Schoenbaum, M., Thompson, E., Justice, M., Zatzick, D., Hamilton, L., McMullen, C. K., et al. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107124 · Cited by 6
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial
Opheim, A., Benth, J. Š., Solli, K. K., Kloster, P. S., Fadnes, L. T., Kunøe, N., Gaulen, Z., & Tanum, L. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107360 · Cited by 6
Self-citation
Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone
Mannelli, P., Swartz, M. S., & Wu, L.-T. T. (2018) · American Journal on Addictions · doi:10.1111/ajad.12763 · Cited by 6
Comparison of naltrexone implant and oral buprenorphine‐naloxone in the treatment of opiate use disorder
Erdogan, A. R., Topcuoğlu, M., Coşkun, M. N., Ci̇nemre, B., Kulaksızoğlu, B., & Kuloğlu, M. M. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2813 · Cited by 6
The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse
Gaulen, Z., Brenna, I. H., Fadnes, L. T., Benth, J. Š., Solli, K. K., Kunøe, N., Opheim, A., & Tanum, L. (2021) · European Addiction Research · doi:10.1159/000518436 · Cited by 6
Self-citation
Medications for Opioid Use Disorder: A Guide for Physicians.
Azhar, N., Chockalingam, R., & Azhar, A. (2020) · Europe PMC (PubMed Central) · Cited by 6
Improving Our Understanding of Substance Use Disorders
Brady, K. T. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18121391 · Cited by 6
Mortality during and following treatment with extended-release naltrexone based on data from two clinical trials
Gjersing, L., Tanum, L., Weimand, B. M., & Solli, K. K. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112737 · Cited by 5
Self-citation
A Review of Relapse in Opioid Use Disorder
Draghmeh, K., Gold, M. S., & Fuehrlein, B. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00672-5 · Cited by 5
Addiction: Sex and gender evidence in alcohol, tobacco use and nicotine addiction, and opioid use disorders
Martin, C. E., Scialli, A. C., & Terplan, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816569-0.00003-6 · Cited by 5
Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update
Leyrer‐Jackson, J. M., Acuña, A. M., & Olive, M. F. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2140039 · Cited by 5
Treating opioid dependence with extended-release naltrexone (XR-NTX) in Ukraine: Feasibility and three-month outcomes
Makarenko, I., Pykalo, I., Springer, S. A., Mazhnaya, A., Marcus, R., Filippovich, S., Дворяк, С., & Altice, F. L. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.05.008 · Cited by 5
Medication Treatments for Opioid Use Disorder: What Is the Impact on Mood and Mood Disorders?
Hassan, A. N., & Nunes, E. V. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0215-x · Cited by 5
Perioperative Management and Analgesia for Patients Taking Buprenorphine and Other Forms of Medication-Assisted Treatment for Substance Abuse Disorders
Scholzen, E. A., Zeng, A. M., & Schroeder, K. M. (2019) · Advances in Anesthesia · doi:10.1016/j.aan.2019.08.002 · Cited by 5
Clinical Trials for Opioid Use Disorder
Blessing, E., Virani, S., & Rotrosen, J. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_304 · Cited by 5
Comparative effectiveness of extended‐release naltrexone versus buprenorphine‐naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population‐based observational data
Lodi, S., Yan, S., Bovell-Ammon, B. J., Christine, P. J., Hsu, H., Bernson, D., Novo, P., Lee, J. D., Rotrosen, J., Liebschutz, J. M., et al. (2025) · Addiction · doi:10.1111/add.70040 · Cited by 4
Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
Marciuch, A., Birkeland, B., Benth, J. Š., Solli, K. K., Tanum, L., Mathisen, I., & Weimand, B. M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17516 · Cited by 4
Self-citation
Pharmacological Treatment of Substance Use Disorders
Srivastava, A. B., LEVIN, F. R., & Nunes, E. V. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_140-1 · Cited by 4
Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis
Qian, G. L., Humphreys, K. N., Goldhaber‐Fiebert, J. D., & Brandeau, M. L. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111112 · Cited by 4
How Should the United States Respond to the Opioid Addiction and Overdose Epidemic?
Humphreys, K. N., & Pollack, H. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-11908-9_10 · Cited by 4
Treatment of Opioid Dependence
Soyka, M. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_12 · Cited by 4
Commentary: Providing technical assistance for the state targeted response for opioid use disorders: Time is of the essence
LEVIN, F. R., & Cates‐Wessel, K. (2018) · American Journal on Addictions · doi:10.1111/ajad.12705 · Cited by 5
A multilevel analysis of changing telehealth availability in opioid use disorder treatment settings: Conditional effects of rurality, the number and types of medication for opioid use disorder available, and time, US, 2016–2023
Pro, G. C., Cantor, J., Willis, D. E., Gu, M., Fairman, B. J., Baloh, J., & Montgomery, B. E. E. (2024) · The Journal of Rural Health · doi:10.1111/jrh.12854 · Cited by 3
Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
Karlsson, A. T., Vederhus, J., Clausen, T., Weimand, B. M., Solli, K. K., & Tanum, L. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811435 · Cited by 3
Self-citation
Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies
Jalali, A. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2350561 · Cited by 3
Changes in mental health during long-term treatment with extended-release naltrexone: A 3-year clinical study of opioid dependent individuals
Solli, K. K., Benth, J. Š., Digranes, L. C. W., Holtan, L., Kunøe, N., & Tanum, L. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.107861 · Cited by 3
Self-citation
Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT
Friedmann, P. D., Dunn, K. E., Nunes, E. V., & O’Brien, C. P. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.11.008 · Cited by 3
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study
Greiner, M. G., Shulman, M., Opara, O., Potter, K. M., Voronca, D., Tafessu, H. M., Hefner, K. R., Hamilton, A., Scheele, C., Ho, R., et al. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107148 · Cited by 3
Engaging healthcare teams to increase access to medications for opioid use disorder
Oberman, R. S., Huynh, A. K., Cummings, K., Resnick, A., Taylor, S. L., Bergman, A. A., & Chang, E. T. (2024) · Health Services Research · doi:10.1111/1475-6773.14371 · Cited by 3
Potential uses of naltrexone in emergency department patients with opioid use disorder
Bradley, E. S., Liss, D. B., Carreiro, S., Brush, D. E., & Babu, K. M. (2019) · Clinical Toxicology · doi:10.1080/15563650.2019.1583342 · Cited by 3
Chapter 14. Opioid Antagonist Treatment of Opioid-Related Disorders
Capata, M., & Hartwell, K. J. (2021) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615373970.kb14 · Cited by 3
Pain intensity in patients using extended‐release naltrexone or opioid agonists and its effect on extended‐release naltrexone treatment outcomes
Juya, F., Solli, K. K., Holtan, L., Sannes, A., Weimand, B. M., Sagen, A. G., Benth, J. Š., Gjerstad, J., Tanum, L., & Mordal, J. (2025) · American Journal on Addictions · doi:10.1111/ajad.70035 · Cited by 2
Self-citation
Treatment initiations and opioid overdoses among recently incarcerated people after adoption of the take-home methadone policy
Barsky, B. A., Yan, S., & Rosenthal, M. B. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112775 · Cited by 2
Evaluation of the New England Office Based Addiction Treatment ECHO: A Tool for Strengthening the Addiction Workforce
Heerema, M. R., Ventura, A. S., Blakemore, S., Montoya, I. D., Gobel, D. E., Kiang, M. V., LaBelle, C. T., & Bazzi, A. R. (2023) · Substance Abuse · doi:10.1177/08897077231179601 · Cited by 2
Attitudes toward extended-release naltrexone treatment for opioid use disorder among African Americans
Rigg, K. K. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111260 · Cited by 2
Emergency department management of opioid use disorder in pediatric patients
Schwarz, E. S., Dietrich, A. M., Sandelich, S., Hooley, G., Rose, E., Ruttan, T., Simon, E. L., Sulton, C., & Wall, J. (2024) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.13265 · Cited by 2
Exploring the Determinants of Treatment Completion Among Youth Who Received Medication-Assisted Treatment in the United States
Adeniran, E. A., Quinn, M., Liu, Y., Brooks, B., & Pack, R. P. (2025) · Healthcare · doi:10.3390/healthcare13070798 · Cited by 2
Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review
Shirk, S. D., Ameral, V., Kraus, S. W., Houchins, J. R., Kelly, M. M., Pugh, K. E., Reilly, E. D., & Desai, N. (2021) · Journal of Dual Diagnosis · doi:10.1080/15504263.2021.1942380 · Cited by 2
Alcohol and Drug Use Disorders
Wakeman, S., & Saitz, R. (2018) · Springer eBooks · doi:10.1007/978-3-319-71812-5_7 · Cited by 9
Psychoeducational Strategies During Outpatient Transition to Extended-Release Naltrexone for Patients With Opioid Use Disorder
Zavod, A., Akerman, S. C., Snow, M. M., Tierney, M., & Sullivan, M. A. (2018) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390318820124 · Cited by 2
Comment on “Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence”
Silverman, B. L., Bloomgren, G., Jain, P., Marcopul, K., Silveira, A. C., Fratantonio, J. L., Sullivan, M. A., & Akerman, S. C. (2018) · Drug Safety · doi:10.1007/s40264-018-0691-x · Cited by 2
Optimizing Treatment for Opioid Use Disorder
Brady, K. T. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21050527 · Cited by 2
Alcohol and Drug Use Disorders
Baca-Atlas, M., Baca-Atlas, S. N., & Fedoriw, K. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-29171-5_6 · Cited by 1
Blood pressure response to extended-release naltrexone in heroin and prescription opioid users and its implications for cardiovascular morbidity
Shi, Z., Langleben, D. D., Rott, D., Albanese, M. A., & Elman, I. (2024) · Journal of Addictive Diseases · doi:10.1080/10550887.2024.2327739 · Cited by 1

Authors: Tanum, L., Solli, K. K., Latif, Z.-E.-H., Benth, J. Š., Opheim, A., Sharma-Haase, K., Krajci, P., & Kunøe, N.
Affiliations: University of Oslo (NO)
Akershus University Hospital (NO)
Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway4Health Services Research Unit, Akershus University Hospital, Lorenskog, Norway
Haukeland University Hospital (NO)
The Norwegian Centre for Addiction Research, The University of Oslo, Oslo, Norway7Department of Addiction Medicine, Vestfold Hospital Trust, Tonsberg, Norway
Department of Addiction Medicine, Oslo University Hospital, Oslo, Norway
Corresponding author: Tanum, Lars
ORCID: Tanum, Lars
Solli, Kristin Klemmetsby
Latif, Zill-e-Huma
Opheim, Arild
Kunøe, Nikolaj
Venue: JAMA Psychiatry
Publisher: American Medical Association (AMA)
Published: 2017-12-01
Volume: 74
Issue: 12
Pages: 1197
ISSN: 2168-622X (ISSN-L)
DOI: 10.1001/jamapsychiatry.2017.3206
PMC: PMC6583381
OpenAlex: W2766969415
Cited by: 253
References: 43
Citations by year: 2026: 13 · 2025: 21 · 2024: 20 · 2023: 15 · 2022: 25 · 2021: 34 · 2020: 30 · 2019: 47 · 2018: 44 · 2017: 4
FWCI: 32.10
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA Psychiatry (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Norges Forskningsråd
Haukeland Universitetssjukehus
Akershus Universitetssykehus
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords: buprenorphine/naloxone, opioid use disorder, heroin use, opioid substitution therapy, abstinence, treatment retention, detoxification, intramuscular injection, non-inferiority, illicit drug use, treatment safety, addiction treatment centers, Norway
MeSH terms: Buprenorphine, Naloxone Drug Combination, Administration, Oral, Adult, Delayed-Action Preparations, Female, Humans, Injections, Intramuscular, Male, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Psychiatric Status Rating Scales, Substance Abuse Detection, Treatment Outcome, Drug Monitoring, Diagnostic and Statistical Manual of Mental Disorders, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks